Assessment of68 Ga-PSMA-11 PET positivity predictive factors in prostate cancer

• Published in: Revista Española de medicina nuclear e imagen molecular (English ed.) 2018, Vol.38 (1), p.22-28
• Main Authors: Gutiérrez-Cardo, A.L, Pérez Duarte, A, García-Argüello, S.F, López Lorenzo, B, Lillo García, M.E, Valdivielso, P
• Format: Article
• Language: English
• Subjects: Radiology
• ISSN: 2253-8089; 2253-8089
• DOI: 10.1016/j.remnie.2018.09.001

Abstract Purpose Positron emission tomography (PET) studies with68 Ga-PSMA-11 (68 Ga-HBED-CC-PSMA) have earned the attention of researchers, due to overexpression of PSMA in the tumoral tissues of prostate cancer. Our aim was to analyze the potential benefit of this radiotracer in the biochemical relapse of prostate cancer. Material and methods This retrospective analysis included 53 studies, performed on 50 male prostate cancer patients referred due to biochemical recurrence. In all cases, previous imaging techniques were negative or inconclusive. Results Of the 53 studies, 36 (68%) were positive. Significant differences were found between the positive and negative PET groups in Gleason's scale, PSA levels, PSAdt, late acquisition and the administration of androgen deprivation therapy during treatment ( p < .05). Regarding PSA levels, 10 (48%) of the 21 patients with PSA < 1 ng/ml, obtained a pathological PET result. When the PSAdt was below six months, 86.7% of the patients obtained an abnormal PET. In the multivariate analysis, only Gleason's scale was associated independently with an abnormal PET result. Conclusions68 Ga-PSMA-11 PET shows a high disease detection rate in patients where other techniques showed negative or doubtful images. Almost 50% of patients with prostate cancer biochemical recurrence and low PSA levels (